TransEnterix, Inc. (TRXC)
(Delayed Data from AMEX)
$2.06 USD
+0.05 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.06 USD
+0.05 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.05 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
TransEnterix (TRXC) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
TransEnterix (TRXC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TransEnterix (TRXC) Flat As Market Gains: What You Should Know
by Zacks Equity Research
TransEnterix (TRXC) closed at $3.72 in the latest trading session, marking no change from the prior day.
Is TransEnterix (TRXC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TRXC) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love TransEnterix (TRXC)
by Zacks Equity Research
Does TransEnterix (TRXC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is TransEnterix (TRXC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TRXC) Outperforming Other Medical Stocks This Year?
What Makes TransEnterix (TRXC) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does TransEnterix (TRXC) have what it takes to be a top stock pick for momentum investors? Let's find out.
TransEnterix (TRXC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
TransEnterix (TRXC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TransEnterix's (TRXC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in TransEnterix (TRXC).
TransEnterix (TRXC) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
TransEnterix (TRXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
What Makes TransEnterix (TRXC) a New Buy Stock
by Zacks Equity Research
TransEnterix (TRXC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Do Options Traders Know Something About TransEnterix (TRXC) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.
TransEnterix (TRXC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
TransEnterix (TRXC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TransEnterix (TRXC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransEnterix (TRXC) delivered earnings and revenue surprises of 47.83% and 11.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
TransEnterix (TRXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Truth About Market Timing - October 06, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
The Keys to Successfully Timing the Markets - September 15, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
The Keys to Successfully Timing the Markets - August 18, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
TransEnterix (TRXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
TransEnterix (TRXC) delivered earnings and revenue surprises of 44.74% and 127.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
TransEnterix (TRXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When Does Market Timing Actually Work? - July 29, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Timing the Market, Is it Possible? - July 07, 2020
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
The Truth About Market Timing - June 17, 2020
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
TransEnterix (TRXC) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
TransEnterix (TRXC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Implied Volatility Surging for TransEnterix (TRXC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to TransEnterix (TRXC) stock based on the movements in the options market lately.
TransEnterix (TRXC) Upgraded to Buy: Here's Why
by Zacks Equity Research
TransEnterix (TRXC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).